Literature DB >> 30370450

Post-retrieval oxytocin facilitates next day extinction of threat memory in humans.

Jingchu Hu1,2, Zijie Wang2, Xiaoyi Feng1, Cheng Long3, Daniela Schiller4,5,6.   

Abstract

RATIONALE: Memories can return to a labile state and become amenable to modification by pharmacological and behavioral manipulations after retrieval. This process may reduce the impact of aversive memories and provide a promising therapeutic technique for the treatment of anxiety disorders. A growing body of evidence suggests that the mammalian neuropeptide oxytocin (OT) plays a role in the regulation of emotional memories in animals. However, the effects of OT on threat memory in humans remain largely unknown.
OBJECTIVES: This study aimed to investigate the effects of OT administration following threat memory retrieval on subsequent memory expression in human participants.
METHODS: In a double-blind, randomized, placebo-controlled, between-subject design, 61 healthy human individuals completed a 3-day experiment. All the participants underwent threat conditioning on day 1. On day 2, the participants were randomized to receive an intranasal dose of OT (40 IU) or placebo after memory retrieval, or an intranasal dose of OT (40 IU) without retrieval. On day 3, the participants were tested for extinction and reinstatement.
RESULTS: On day 3, all groups showed equivalent stimulus discrimination during the early phase of extinction. However, the group that received OT following a memory reminder showed a greater decline in stimulus discrimination by the late phase of extinction relative to the two other groups.
CONCLUSIONS: The results indicate that OT did not block reconsolidation to prevent the return of threat memory but rather interacted with post-retrieval processes to facilitate next day extinction. The study provides novel preliminary evidence for the role of OT in human threat memory.

Entities:  

Keywords:  Extinction; Fear conditioning; Oxytocin; Reactivation; Reconsolidation

Mesh:

Substances:

Year:  2018        PMID: 30370450      PMCID: PMC6374199          DOI: 10.1007/s00213-018-5074-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  37 in total

1.  Prefrontal cortex long-term potentiation, but not long-term depression, is associated with the maintenance of extinction of learned fear in mice.

Authors:  Cyril Herry; Rene Garcia
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

2.  Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval.

Authors:  K Nader; G E Schafe; J E Le Doux
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 3.  A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research.

Authors:  Elayne MacDonald; Mark R Dadds; John L Brennan; Katrina Williams; Florence Levy; Avril J Cauchi
Journal:  Psychoneuroendocrinology       Date:  2011-03-23       Impact factor: 4.905

4.  Consolidation of fear extinction requires NMDA receptor-dependent bursting in the ventromedial prefrontal cortex.

Authors:  Anthony Burgos-Robles; Ivan Vidal-Gonzalez; Edwin Santini; Gregory J Quirk
Journal:  Neuron       Date:  2007-03-15       Impact factor: 17.173

5.  Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder.

Authors:  Alain Brunet; Scott P Orr; Jacques Tremblay; Kate Robertson; Karim Nader; Roger K Pitman
Journal:  J Psychiatr Res       Date:  2007-06-22       Impact factor: 4.791

Review 6.  Stimuli and consequences of dendritic release of oxytocin within the brain.

Authors:  I D Neumann
Journal:  Biochem Soc Trans       Date:  2007-11       Impact factor: 5.407

7.  Dissociating response systems: erasing fear from memory.

Authors:  Marieke Soeter; Merel Kindt
Journal:  Neurobiol Learn Mem       Date:  2010-04-08       Impact factor: 2.877

8.  Beyond extinction: erasing human fear responses and preventing the return of fear.

Authors:  Merel Kindt; Marieke Soeter; Bram Vervliet
Journal:  Nat Neurosci       Date:  2009-02-15       Impact factor: 24.884

9.  A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder.

Authors:  Adam J Guastella; Alexandra L Howard; Mark R Dadds; Philip Mitchell; Dean S Carson
Journal:  Psychoneuroendocrinology       Date:  2009-02-25       Impact factor: 4.905

Review 10.  Attachment, aggression and affiliation: the role of oxytocin in female social behavior.

Authors:  Anne Campbell
Journal:  Biol Psychol       Date:  2007-09-06       Impact factor: 3.251

View more
  5 in total

1.  Navigating the garden of forking paths for data exclusions in fear conditioning research.

Authors:  Tina B Lonsdorf; Maren Klingelhöfer-Jens; Marta Andreatta; Tom Beckers; Anastasia Chalkia; Anna Gerlicher; Valerie L Jentsch; Shira Meir Drexler; Gaetan Mertens; Jan Richter; Rachel Sjouwerman; Julia Wendt; Christian J Merz
Journal:  Elife       Date:  2019-12-16       Impact factor: 8.140

2.  Selective sub-nucleus effects of intra-amygdala oxytocin on fear extinction.

Authors:  Ozge Gunduz-Cinar; Emma T Brockway; Laura I Castillo; Gabrielle A Pollack; Tugce Erguven; Andrew Holmes
Journal:  Behav Brain Res       Date:  2020-07-09       Impact factor: 3.332

3.  Editorial: the psychopharmacology of extinction-from theory to therapy.

Authors:  Amy L Milton; Andrew Holmes
Journal:  Psychopharmacology (Berl)       Date:  2019-01       Impact factor: 4.530

4.  Emotional remodeling with oxytocin durably rescues trauma-induced behavioral and neuro-morphological changes in rats: a promising treatment for PTSD.

Authors:  Claire Le Dorze; Antonella Borreca; Annabella Pignataro; Martine Ammassari-Teule; Pascale Gisquet-Verrier
Journal:  Transl Psychiatry       Date:  2020-01-27       Impact factor: 6.222

5.  Depressive symptoms and social context modulate oxytocin's effect on negative memory recall.

Authors:  Shiu F Wong; Christopher Cardoso; Mark A Orlando; Christopher A Brown; Mark A Ellenbogen
Journal:  Soc Cogn Affect Neurosci       Date:  2021-12-30       Impact factor: 3.436

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.